PMID- 38135634 OWN - NLM STAT- MEDLINE DCOM- 20240301 LR - 20240410 IS - 2152-2669 (Electronic) IS - 2152-2669 (Linking) VI - 24 IP - 3 DP - 2024 Mar TI - Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma. PG - e104-e111.e1 LID - S2152-2650(23)02186-9 [pii] LID - 10.1016/j.clml.2023.11.008 [doi] AB - In multiple myeloma (MM) significant variation in progression-free survival (PFS) and overall survival (OS) is observed. We examined the outcomes of 1557 MM patients stratified into short (<2 years), medium (between 2 and 5 years) and long (>5 years) PFS. Short PFS occurred in 758 patients (48.7%), medium in 561 patients (36.2%), and long in 238 patients (15.3%). Median post-progression PFS was 9.2 months (95% CI: 8.1-11.0) in the short PFS and 33.1 months (95% CI: 29.0-42.1; P < .001) in the long PFS group. Median post-progression OS was 26.6 months (95% CI: 23.9-29.8) in the short PFS and 87.8 months (95% CI: 71.3- NR; P < .001) in the long PFS. Worse survival in the short PFS was irrespective of high risk (HR) fluorescence in situ hybridization (FISH) features, defined as deletion 17p and/or translocation t(4;14), t(14;16), t(14;20). In a multivariable analysis short PFS was associated with HR FISH, extramedullary plasmacytoma, plasma cell labeling index >/=2% at diagnosis, nonimmunoglobulin G isotype, treatment without autologous stem cell transplantation and achieving less than very good partial remission. In conclusion, the duration of the PFS significantly influences survival, regardless of HR cytogenetic features. Therefore, it should be considered an important parameter for risk stratification in patients experiencing a relapse. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Goldman-Mazur, Sarah AU - Goldman-Mazur S AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Visram, Alissa AU - Visram A AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN; Division of Hematology, Ottawa Hospital Research Institute, Ontario, Canada. FAU - Rajkumar, S Vincent AU - Rajkumar SV AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Kapoor, Prashant AU - Kapoor P AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Dispenzieri, Angela AU - Dispenzieri A AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Lacy, Martha Q AU - Lacy MQ AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Gertz, Morie A AU - Gertz MA AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Buadi, Francis K AU - Buadi FK AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Hayman, Suzanne R AU - Hayman SR AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Dingli, David AU - Dingli D AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Kourelis, Taxiarchis AU - Kourelis T AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Gonsalves, Wilson AU - Gonsalves W AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Warsame, Rahma AU - Warsame R AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Muchtar, Eli AU - Muchtar E AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Leung, Nelson AU - Leung N AD - Division of Nephrology, Mayo Clinic Rochester, Rochester, MN. FAU - Kyle, Robert A AU - Kyle RA AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. FAU - Kumar, Shaji K AU - Kumar SK AD - Division of Hematology, Mayo Clinic Rochester, Rochester, MN. Electronic address: kumar.shaji@mayo.edu. LA - eng PT - Journal Article DEP - 20231127 PL - United States TA - Clin Lymphoma Myeloma Leuk JT - Clinical lymphoma, myeloma & leukemia JID - 101525386 SB - IM MH - Humans MH - *Multiple Myeloma/diagnosis/genetics/therapy MH - *Hematopoietic Stem Cell Transplantation MH - Treatment Outcome MH - In Situ Hybridization, Fluorescence MH - Transplantation, Autologous MH - Neoplasm Recurrence, Local MH - Disease Progression MH - Retrospective Studies OTO - NOTNLM OT - Myeloma OT - Outcome OT - Progression OT - Progression-free survival COIS- Disclosure Prashant Kapoor: Research Funding: Takeda, Sanofi, Karyopharm, Glaxo SmithKline, Regeneron Pharmaceuticals, Ichnos Sciences, Amgen. Cosultancy: Sanofi, Pharmacyclics, BeiGene, Cellectar, Karyopharm; Angela Dispenzieri: Consultancy and Research Funding: Janssen. Research Funding: Takeda, Alnylam, Pfizer. Consultancy: Oncopeptides, Sorrento Therapeutics; Morie A. Gertz: Advisory Board: Ionis Pharmaceuticals. Consultancy: Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena. Data Safetly & Monitoring: AbbVie Inc, Celgene Corporation. Honoraria: Akcea Therapeutics, Ambry Genetics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme. Stock option: Aurora Biopharma; David Dingli: Consultancy: Alexion, Apellis, GSK, Sanofi, Janssen. Research Funding: Novartis; Shaji Kumar: Consultancy and Research Funding: BMS, Amgen, Roche-Genentech. Consultancy, Membership on an entity's Board of Directors or advisory committees and Research Funding: Abbvie, Takeda, Janssen, KITE, Astra-Zeneca. Research Funding: Tenebio, Carsgen, Merck, Novartis, Sanofi. Consultancy: Beigene, Oncopeptides, Bluebird Bio. Consultancy and Honoraria: Antengene. Membership on an entity's Board of Directors or advisory committees and Research Funding: Adaptive, Celgene. EDAT- 2023/12/23 12:42 MHDA- 2024/03/01 06:44 CRDT- 2023/12/22 22:01 PHST- 2023/10/27 00:00 [received] PHST- 2023/11/23 00:00 [accepted] PHST- 2024/03/01 06:44 [medline] PHST- 2023/12/23 12:42 [pubmed] PHST- 2023/12/22 22:01 [entrez] AID - S2152-2650(23)02186-9 [pii] AID - 10.1016/j.clml.2023.11.008 [doi] PST - ppublish SO - Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):e104-e111.e1. doi: 10.1016/j.clml.2023.11.008. Epub 2023 Nov 27.